Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Hypomethylating agents in AML

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, outlines the advantages and underuse of hypomethylating agents in acute myeloid leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).